Welcome To DiagnosticsCRC  
 

 

The CRC for Diagnostics officially ceased operations in September 2007

Some of the research programs from the CRC for Diagnostics have formed the basis of a new CRC for Biomarker Translation.

The new CRC will develop antibody-based therapeutics and diagnostic tests that target cell surface molecules (biomarkers) expressed by white blood cells or cancer cells. These antibodies or “magic bullets" target the cells involved in major diseases, including autoimmune disease and cancers. The new therapies and tests are expected to transform the management of these diseases and make Australia a competitive force in the rapidly growing, multi-billion dollar antibody therapeutic market.

For further details about the new CRC for Biomarker Translation, contact Professor Mark Hogarth Tel +61 03 9287 0685 or email pmhogarth@burnet.edu.au

Mission CDx, The Diagnostics CRC, successfully developed and exploited diagnostic platforms to enable more patient-specific screening for predisposition of selected diseases and medical conditions.   Australia CRC The success of this CRC was attributed to a productive merger of first class researchers and end-users in a strong alliance of research and commercialisation expertise. Specialisation CDx brought together leading Australian-based diagnostic research organisations and one of the country's largest privately-owned pathology laboratories.
Copyright © 2005 Diatech Pty Ltd. All Rights Reserved. Designed by Charles Liu.